Organic Active Ingredients TRIZ Cases

Ketone-potentiated antiepileptic compounds combine seizure suppression with metabolic ketone production to treat refractory epilepsy.

A composite of psyllium husk, oat fiber, and gums replaces synthetic agents to maintain tablet flowability and compressibility.

Antrodia camphorata compound SY-1 addresses ineffective standard therapies by lowering blood sugar and lipids while improving insulin secretion.

Benzoxadiazole-polyamine probes detect tumors via active transport, avoiding healthy tissue damage from non-selective agents.

A neurotoxic substance stabilizes voltage-dependent sodium channels in renal neurons to induce targeted cell death.

Heterocyclic compounds inhibit DYRK1A activity to treat neurological disorders by normalizing protein levels and mitigating disease progression.

Heterocyclic compounds of Formula 1, 2, or 3 selectively bind androgen receptors to treat muscle wasting without traditional steroid side effects.

Chitosan hydrogel microparticles reduce astrocyte reactions and promote vascularization to overcome glial scar inhibition during spinal cord repair.

Structural optimization of benzimidazole compounds enhances bioavailability to cross the blood-brain barrier and treat cognitive disorders.

A DACOs-type NNRTI amino acid ester derivative modifies molecular structure to enhance bioavailability and pharmacokinetic properties.

Sequentially applies reduced-strength imiquimod cream followed by photodynamic therapy to clear actinic keratosis while minimizing application site reactions.

Specific compounds activate PKM2 by locking the enzyme in an active conformation, resolving selectivity issues in cancer therapy.

Novel GPR40 agonists delay islet function diminution and improve blood sugar control by activating glucose-dependent insulin release.

Crystal form A of tenofovir prodrug improves oral bioavailability by replacing phosphate groups with phosphonamidate bonds to reduce renal toxicity.

Asymmetric molecular design enhances selectivity for PI3K and mTOR kinases, reducing off-target toxicity in cancer treatment.

Novel quinuclidine ligands target the nicotinic α7 receptor to address cognitive deficits and negative symptoms in schizophrenia.

Alkali metal silicate converts asenapine maleate to high purity free base, resolving low skin permeation of the protonated salt form.

A poly-gamma-glutamic acid composition suppresses adipogenic gene expression and reduces lipid accumulation in preadipocyte cells.

Formula I compounds inhibit eukaryotic elongation factor 2 kinase activity to limit EF2 phosphorylation in cancer and radiation injury treatment.

Formula compounds inhibit cancer cell growth and stimulate M1 polarization by targeting PI3Kγ pathways.

Optimized propylene glycol concentrations enable high-concentration apixaban solutions, reducing dose volumes for patient compliance.

Merges targeted antibody internalization with Bcl-2 inhibition to resolve treatment complexity while improving lymphoma efficacy.

New pyrrole compounds inhibit anti-apoptotic Bcl-2 proteins, reactivating cell death pathways to treat chemoresistant cancers and autoimmune diseases.

Tritoqualine reduces fibrosis scores by inhibiting collagen formation, addressing limited survival benefits from existing pirfenidone treatments.

Lithium borohydride reduces esters to ospemifene, avoiding explosive reagents and uncontrolled hydrogen production.

Selective quinoline derivatives antagonize TLR7 and 8, reducing interferon levels and side effects in systemic lupus erythematosus.

Amorphous solid dispersion immobilizes hydrophobic drugs in a polymer matrix, resolving the trade-off between stability and absorption.

Carbonyl-modified nitrobenzene derivatives reduce viral loads while lowering toxicity compared to ribavirin.

Formula I pyrazoles inhibit MAGL to treat neuropathic pain and neurological disorders.

Lipid nanoparticles deliver siRNA to liver cells, silencing HBV genes and reducing viral replication.

Eutectic form A of Elagolix and pyrimethamine resists hygroscopicity by forming a stable crystal lattice that prevents moisture absorption.

Chewable hyaluronic acid composition hydrates buccal mucosa to stimulate salivation and intestinal peristalsis, reducing postoperative ileus recovery time.

Asymmetric polymer vesicles resolve acute myeloid leukemia treatment contradictions by enabling precise tumor targeting and controlled intracellular release.

Ethyl eicosapentanoate composition reduces liver inflammation and steatosis in non-diabetic subjects.

Oligosaccharide compositions stimulate bile salt secretion to enhance lipid digestion in infants.

Amiloride derivatives inhibit ENaC, NHE1, and NCX1 ion channels simultaneously, restoring aberrant signaling in skin inflammation.

Tannic acid facilitates benzoate transport across the blood-brain barrier, reducing required dosages while enhancing efficacy for CNS treatment.

A topical composition blends Candelilla wax, Shea nut butter, and essential oils to deliver anti-inflammatory and antimicrobial action directly to affected tissue.

An oligopeptide composition over-activates cancer cell autophagy to boost anticancer drug activity while minimizing normal tissue toxicity.

Aryl sulfonamide inhibitors target the STAT3 dimer interface to suppress tumor growth while minimizing systemic toxicity.

Spring-loaded auto-injector delivers stabilized naloxone, enabling untrained users to treat opioid toxicity without manual operation.

Bioadhesive nanoparticles anchor chondroinductive agents into cartilage extracellular matrix, preventing rapid joint clearance and improving retention.

Fc-free antibody variants expand gamma delta T-cells by eliminating cytotoxic ADCC effects.

Compounds targeting the CAMK2A enzyme prevent neuronal death and improve motor function after stroke, extending the therapeutic window beyond 4.5 hours.

Bryostatin-1 activates PKC-delta to inhibit neutrophil infiltration, reducing inflammation severity in transplantation injuries.

Administering buprenorphine with real-time monitoring to resolve diagnostic contradictions between addiction treatment and autonomic dysfunction management.

Treats seronegative individuals with antiviral prophylaxis to prevent HSV transmission despite partner non-compliance.